Abstract:Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy that presents with highly heterogenous clinical syndromes. We perform cross-sectional data-driven discovery of independent patterns of brain atrophy and hypometabolism across the entire PSP spectrum. We then use these patterns to predict specific clinical features and to assess their relationship to phenotypic heterogeneity. We included 111 patients with PSP (60 with Richardson syndrome and 51 with cortical and subcortical variant subtypes). Ninety-one were used as the training set and 20 as a test set. The presence and severity of granular clinical variables such as postural instability, parkinsonism, apraxia and supranuclear gaze palsy were noted. Domains of akinesia, ocular motor impairment, postural instability and cognitive dysfunction as defined by the Movement Disorders Society criteria for PSP were also recorded. Non-negative matrix factorization was used on cross-sectional MRI and fluorodeoxyglucose-positron emission tomography (FDG-PET) scans. Independent models for each as well as a combined model for MRI and FDG-PET were developed and used to predict the granular clinical variables. Both MRI and FDG-PET were better at predicting presence of a symptom than severity, suggesting identification of disease state may be more robust than disease stage. FDG-PET predicted predominantly cortical abnormalities better than MRI such as ideomotor apraxia, apraxia of speech and frontal dysexecutive syndrome. MRI demonstrated prediction of cortical and more so sub-cortical abnormalities, such as parkinsonism. Distinct neuroanatomical foci were predictive in MRI- and FDG-PET-based models. For example, vertical gaze palsy was predicted by midbrain atrophy on MRI, but frontal eye field hypometabolism on FDG-PET. Findings also differed by scale or instrument used. For example, prediction of ocular motor abnormalities using the PSP Saccadic Impairment Scale was stronger than with the Movement Disorders Society Diagnostic criteria for PSP oculomotor impairment designation. Combination of MRI and FDG-PET demonstrated enhanced detection of parkinsonism and frontal syndrome presence and apraxia, cognitive impairment and bradykinesia severity. Both MRI and FDG-PET patterns were able to predict some measures in the test set; however, prediction of global cognition measured by Montreal Cognitive Assessment was the strongest. MRI predictions generalized more robustly to the test set. PSP leads to neurodegeneration in motor, cognitive and ocular motor networks at cortical and subcortical foci, leading to diverse yet overlapping clinical syndromes. To advance understanding of phenotypic heterogeneity in PSP, it is essential to consider data-driven approaches to clinical neuroimaging analyses.

Midbrain/pons Area Ratio and Clinical Features Predict the Prognosis of Progressive Supranuclear Palsy

Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials

Value of magnetic resonance Parkinsonism index in prognosis of progressive supranuclear palsy

Gray matter atrophy in progressive supranuclear palsy: meta-analysis of voxel-based morphometry studies

Clinical Features of Progressive Supranuclear Palsy.

Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center

Clinical and MRI analysis of progressive supranuclear palsy：a report of 12 cases

Progressive supranuclear palsy：A report of 7 cases and literature review

Predicting the Prognosis of Multiple System Atrophy Using Cluster and Principal Component Analysis.

Long-standing preservation of levodopa response in progressive supranuclear palsy

Progressive Supranuclear Palsy: What Do We Know about It?

Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy

Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy

The Role of Brain Perivascular Space Burden in Early-Stage Parkinson’s Disease

Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials

Prediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging

Associated factors for quality of life in patients with progressive supranuclear palsy

Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.

Retinal Thinning as a Marker of Disease Severity in Progressive Supranuclear Palsy

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Patterns of brain volume and metabolism predict clinical features in the progressive supranuclear palsy spectrum